PMCB

PharmaCyte Biotech, Inc. Common Stock

0.36

USD

-0.02

-4.05%

Nov 06, 15:03 UTC -5

Closed

After-Market

0.36

0.00

0.00%

PharmaCyte Biotech, Inc. Common Stock (PMCB) Earnings

PMCB Earnings Reports

Positive Surprise Ratio

PMCB beat 2 of 4 last estimates.

50%

Next Report

Date of Next Report

Dec 16, 2026

Estimate for Q2 27 (Revenue/ EPS)

Implied change from Q1 27 (Revenue/ EPS)

Implied change from Q2 26 (Revenue/ EPS)

PharmaCyte Biotech, Inc. Common Stock earnings per share and revenue

On Sep 14, 2026, PMCB reported earnings of -0.54 USD per share (EPS) for Q1 27, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a -2.47% price change (close before vs. close after earnings).

Looking ahead to Q2 27, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

ZOETIS INC.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.52

Actual

$1.75

Surprise

+14.64%

Amylyx Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.38

Surprise

+1.04%

Guardian Pharmacy Services, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.30

Actual

$0.33

Surprise

+7.84%

Xeris Biopharma Holdings, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.02

Actual

$0.06

Surprise

+144.90%

Cronos Group Inc. Common Share

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.03

Actual

$0.04

Surprise

+17.65%

Collegium Pharmaceutical, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.89

Actual

$1.96

Surprise

+3.17%

Ironwood Pharmaceuticals, Inc. - Class A

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.32

Actual

$0.36

Surprise

+9.16%

ARS Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.32

Actual

-$0.36

Surprise

-11.15%

Profound Medical Corp. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.18

Actual

-$0.21

Surprise

-11.41%

Akebia Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.03

Actual

-$0.04

Surprise

-6.95%

FAQ

What were PharmaCyte Biotech, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2027?

For Q1 2027, PharmaCyte Biotech, Inc. Common Stock reported EPS of -$0.54, missing estimates by --, and revenue of $0.00, -- -- expectations.

How did the market react to PharmaCyte Biotech, Inc. Common Stock's Q1 2027 earnings?

The stock price moved down -2.47%, changed from $0.39 before the earnings release to $0.38 the day after.

When is PharmaCyte Biotech, Inc. Common Stock expected to report next?

The next earning report is scheduled for Dec 16, 2026.

What are the forecasts for PharmaCyte Biotech, Inc. Common Stock's next earnings report?

Based on -- analysts, PharmaCyte Biotech, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q2 2027.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.